History

Foundation:

ScheBo^® • Biotech AG was founded in 1989 by the biochemists and molecular biologists Ursula Scheefers-Borchel, Ph.D., and Hans Scheefers, Ph.D.

Unique Selling Proposition:

Innovative diagnostics:

In 1993 ScheBo^® • Biotech AG launched worldwide the first non-invasive, cheap routine test procedure for monitoring the exocrine function of the pancreas. Today well reputed clinicians and medical text books regard the ScheBo^® • Pancreatic Elastase 1 ELISA, based on two monoclonal antibodies, as the "gold-standard" for non-invasive pancreatic exocrine function testing. ScheBo^® • Biotech AG is world market leader for this FDA-cleared product. Continuous innovation, strong customer focus and our problem solving philosophy have made ScheBo^® • Biotech AG a leading biopharmaceutical company.

Closing a gap:

In 1998 ScheBo^® • Biotech AG launched the ScheBo^® • Tumor M2-PK™ EDTA-Plasma Test, the first test worldwide that is able to detect a metabolic state, specific for 11 cancer entities, e.g. colon/rectum, gastric, pancreas, esophagus, breast, lung, prostate, kidney, renal, and cancer of the ovary. The predictive value of Tumor M2-PK reflects tumor activity and aggressiveness and gives clinicians additional information that is not provided by state of the art procedures. Thus, the ScheBo^® • Tumor M2-PK™ EDTA-Plasma Test closes a gap in the management of cancer treatment in clinical practice.

Fighting cancer, colorectal cancer screening:

In 2003 ScheBo^® • Biotech AG launched the ScheBo^® • Tumor M2-PK™ Stool Test, the first test detecting pyruvate kinase in stool, a new tool for colorectal cancer screening. This patented test is superior to the well-known occult blood stool tests. The new procedure has a sensitivity of 85% and a specificity of 83%. 2007 ScheBo^® • Biotech AG launched the ScheBo^® • M2-PK Quick™ Test, a worldwide new lateral flow test for colorectal cancer screening. Thereby ScheBo^® • Biotech AG hopes to be able to significantly improve colorectal cancer patients′ chances of being cured. The crucial element is a patented procedure for determining Tumor M2-PK in stool samples.

Fighting BSE:

In 2000 and 2004 ScheBo^® • Biotech AG launched different ScheBo^® • Brainostic™ Tests which allow the detection of brain and spinal cord (risk material) in meat products, thus providing optimal consumer protection. The patents for both, the GFAP- and NSE-based tests, are owned by ScheBo^® • Biotech AG.

Therapeutic cancer product focus:

ScheBo^® • Biotech AG possesses an excellent pipeline of novel, small anticancer drugs. The outstanding preclinical results already obtained will lead to clinical trials proving a worldwide novel cancer therapy strategy.